Advertisement

Pretreatment with ICRF-187 Protects Against the Chronic Cardiac Toxicity Produced by Very Large Cumulative Doses of Doxorubicin in Beagle Dogs

  • V. J. Ferrans
  • E. H. Herman
  • R. L. Hamlin
Part of the Developments in Oncology book series (DION, volume 53)

Abstract

The optimal use of anthracyclines, such as doxorubicin and daunoruoicin, in cancer chemotherapy is hampered by the serious cardiotoxicity that these agents produce when administered to patients. This cardiac toxicity can be acute, subacute and chronic. The acute cardiotoxicity is manifested immediately after the drug is given and consists of hypotension and electrocardiographic changes, which have been attributed to acute, drug-induced release of histamine. The subacute toxicity is rare and is clinically evident in the form of transient myocarditis and pericarditis. The chronic toxicity is the most important and consists of dilated cardiomyopathy, which may have a delayed onset, is often fatal, and usually occurs when the drug is given in cumulative doses which exceed 450 mg/m2 (1).

Keywords

Cardiac Lesion Electrocardiographic Change Central Chain Subacute Toxicity Acute Cardiotoxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Myers, C.E. (1987) Proc. Organ Directed Toxicities of Anticancer Drugs, First International Symposium. Burlington, VT, June 4–6, p. 5.Google Scholar
  2. 2.
    Myers, C.E., Gianni, L., Simone, C.B., Klecker, R., and Greene R. (1982) Biochemistry 21: 1707–1713.PubMedCrossRefGoogle Scholar
  3. 3.
    Creighton, A.M., Hellman, K. and Whitecross S. (1969) Nature 222: 384–385.PubMedCrossRefGoogle Scholar
  4. 4.
    Woodman, R.J., Cysyk, R.C., Kline, I., Gang, M. and Venditti, J.M. (1975) Cancer Chemother. Rep. 59: 689–695.PubMedGoogle Scholar
  5. 5.
    Giuliani, F., Casazza, A.M., Di Marco, A. and Savi, G. (1981) Cancer Treat. Rep. 65: 267–276.PubMedGoogle Scholar
  6. 6.
    Herman, E.H., Mhatre, R.M. and Chadwick, DP. (1974) Toxicol. Appl. Pharmacol. 27: 517–526.PubMedCrossRefGoogle Scholar
  7. 7.
    Herman, E.H., Ardalan, B., Bier, C., Warakdevar, V. and Krop, S. (1979) Cancer Treat. Rep. 63: 89–92.PubMedGoogle Scholar
  8. 8.
    Wang, G., Finch, M.D., Trevan, D. and Hellman, K. (1981) Br. J. Cancer 43: 871–877.PubMedCrossRefGoogle Scholar
  9. 9.
    Herman, E.H., El-Hage, A.N., Ferrans, V.J. and Witiak, D.T. (1983) Res. Commun. Chem. Pathol. Pharmacol. 40: 217–231.PubMedGoogle Scholar
  10. 10.
    Herman, E.H., El-Hage, A.N., Creighton, A.M., Witiak, D.T. and Ferrans, V.J. (1985) Res, Commun. Chem. Pathol. Pharmacol. 48: 39–55.PubMedGoogle Scholar
  11. 11.
    El-Hage, A.N., Herman, E.H., Yang, G.C., Crouch, R.K. and Ferrans, V.J. (1986) Res. Commun. Chem. Pathol. Pharmacol. 52: 341–360.PubMedGoogle Scholar
  12. 12.
    El-Hage, A.N., Herman, E.H. and Ferrans, V.J. (1983) Toxicology 28: 295–303.PubMedCrossRefGoogle Scholar
  13. 13.
    El-Hage, A.N., Herman, E.H. and Ferrans, V.J. (1981) Res. Commun. Chem. Pathol. Pharmacol. 33: 509–523.PubMedGoogle Scholar
  14. 14.
    Herman, E.H. and Ferrans, V.J. (1981) Cancer Res. 41: 3436–3440.PubMedGoogle Scholar
  15. 15.
    Herman, E.H. and Ferrans, V.J. (1983) Drugs Exp. Clin. Res. 9: 483–490.Google Scholar
  16. 16.
    Herman, E.H., Ferrans, V.J., Myers, C.E. and Van Vleet, J.F. (1985) Cancer 45: 276–281.Google Scholar
  17. 17.
    Herman, E.H. and Ferrans, V.J. (1983) Lab. Invest. 49: 69–77.PubMedGoogle Scholar
  18. 18.
    Herman, E.H., Ferrans, V.J., Jordan, W. and Ardalan, B. (1981) Res. Commun. Chem. Pathol. Pharmacol. 31: 85–97.PubMedGoogle Scholar
  19. 19.
    Herman, E.H., El-Hage, A.N., Ferrans, V.J. and Ardalan, B. (1985) Toxicol. Appl. Pharmacol. 78: 202–214.PubMedCrossRefGoogle Scholar
  20. 20.
    Herman, E.H. and Ferrans, V.J. (1986) Cancer Chemother. Pharmacol. 16: 102–106.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1988

Authors and Affiliations

  • V. J. Ferrans
  • E. H. Herman
  • R. L. Hamlin

There are no affiliations available

Personalised recommendations